JNK-IN-7: Selective Covalent JNK Inhibitor for MAPK and Apoptosis Research

Executive Summary: JNK-IN-7 is a highly selective covalent inhibitor of JNK1, JNK2, and JNK3, with IC₅₀ values of 1.54 nM, 1.99 nM, and 0.75 nM, respectively (APExBIO). It inhibits JNK activity by covalently binding to the Cys116 residue of JNK2, blocking c-Jun phosphorylation (JNK-IN-7: Selective JNK Inhibitor for Advanced MAPK Research). JNK-IN-7 also suppresses IRAK-1-dependent E3 ligase activity of Pellino 1 at concentrations between 1–10 µM, demonstrating modulation of innate immune signaling. The compound is soluble at ≥24.7 mg/mL in DMSO and is insoluble in water and ethanol. It serves as a robust tool for apoptosis, inflammation, and immune response assays (Miao et al., 2023).

Biological Rationale

JNKs (c-Jun N-terminal kinases) are key serine/threonine kinases involved in the MAPK signaling cascade. They regulate cell proliferation, apoptosis, and inflammatory responses (Miao et al., 2023). Dysregulation of JNK pathway activity is implicated in various pathological processes, including inflammatory diseases and cancer. Pharmacological inhibition of JNKs allows researchers to dissect crosstalk between apoptosis and immune signaling, especially in models of infection or tissue injury. JNK-IN-7, as a selective covalent JNK inhibitor, is engineered for high specificity, minimizing off-target effects common with earlier JNK inhibitors. Its use has enabled mechanistic studies in cell models of inflammation, such as Candida krusei-induced apoptosis in bovine mammary epithelial cells (BMECs), where both TLR2/ERK and JNK/ERK pathways mediate cell death (Miao et al., 2023).

Mechanism of Action of JNK-IN-7

JNK-IN-7 acts by covalently binding the cysteine 116 residue (Cys116) in the ATP-binding site of JNK2. This irreversible interaction blocks ATP access and inhibits kinase activity. The result is potent suppression of downstream phosphorylation of c-Jun, a direct JNK substrate. At higher concentrations (1–10 µM), JNK-IN-7 can also inhibit IRAK-1-dependent E3 ligase activity of Pellino 1, impacting the Toll receptor signaling pathway and modulating innate immune responses. This dual mechanism allows selective modulation of both apoptosis and immune signaling in experimental systems. The compound's high selectivity is evidenced by low nanomolar IC₅₀ values across JNK isoforms and minimal activity against unrelated kinases (APExBIO).

Evidence & Benchmarks

• JNK-IN-7 inhibits JNK1, JNK2, and JNK3 with IC₅₀ values of 1.54 nM, 1.99 nM, and 0.75 nM, respectively (APExBIO).
• Selective inhibition of c-Jun phosphorylation in cell-based assays confirms target engagement (JNK-IN-7: Selective JNK Inhibitor for Advanced MAPK Research).
• At 1–10 µM, JNK-IN-7 inhibits Pellino 1 E3 ligase activity, modulating Toll-like receptor signaling (APExBIO).
• BMEC apoptosis induced by Candida krusei involves both JNK/ERK and TLR2/ERK signaling, establishing JNK as a pivotal node in infection-driven apoptosis (Miao et al., 2023, Table 2).
• JNK-IN-7 is not soluble in water or ethanol, but is soluble at ≥24.7 mg/mL in DMSO, ensuring compatibility with most biochemical assays (APExBIO).

Applications, Limits & Misconceptions

JNK-IN-7 is widely deployed in studies of MAPK pathway modulation, apoptosis assays, and innate immune signaling. It is especially valuable in models where selective JNK inhibition is needed, such as pathogen-induced apoptosis or inflammatory response research. For example, Miao et al. showed that JNK inhibition alters BMEC apoptosis during Candida krusei infection, clarifying the dual role of JNK/ERK and TLR2/ERK cascades (Miao et al., 2023).

This article extends the foundational overview in JNK-IN-7: Selective JNK Inhibitor for Advanced MAPK Research by providing new benchmarks for immune pathway modulation and updated solubility data. For robust deployment in complex cell models or inflammation studies, see JNK-IN-7 (SKU A3519): Scenario-Driven Solutions for Repro..., which details workflow optimization steps. For comprehensive strategic context, Decoding JNK Signaling: Strategic Insights for Translatio... discusses translational and preclinical implications.

Common Pitfalls or Misconceptions

• JNK-IN-7 is not a pan-kinase inhibitor; it does not significantly affect ERK, p38, or unrelated kinases at recommended concentrations.
• It is insoluble in water and ethanol; improper solvent use will result in precipitation and assay failure.
• JNK-IN-7’s effects on IRAK-1/Pellino 1 require higher concentrations (1–10 µM) than those needed for JNK inhibition.
• Long-term storage of JNK-IN-7 solutions reduces potency; always prepare fresh solutions for experiments (APExBIO).
• JNK-IN-7 cannot distinguish between JNK isoforms in complex lysates; genetic tools may be needed for isoform-specific studies.

Workflow Integration & Parameters

JNK-IN-7 is supplied as a solid and should be stored at -20°C. Stock solutions should be prepared in DMSO (≥24.7 mg/mL) and used immediately to avoid degradation. For in vitro cell-based assays, working concentrations typically range from 0.01–10 µM, depending on the target pathway and cell type. Avoid repeated freeze-thaw cycles. Ensure DMSO content in assays does not exceed 0.1–0.2% v/v to minimize cytotoxicity.

For apoptosis and MAPK signaling studies, JNK-IN-7 enables precise temporal inhibition of JNK, facilitating mechanistic dissection of c-Jun phosphorylation and downstream apoptotic events. In immune modulation assays, higher concentrations can probe cross-talk with IRAK-1 and Toll receptor signaling. Reference protocols and scenario-driven guidance are available in JNK-IN-7 (SKU A3519): Scenario-Driven Solutions for Repro....

Conclusion & Outlook

JNK-IN-7 (SKU A3519) from APExBIO represents the current standard for selective, covalent inhibition of JNK kinases. Its defined potency, solubility profile, and dual action across kinase and immune signaling pathways make it indispensable for researchers investigating apoptosis, MAPK signaling, and inflammation. As demonstrated in models of pathogen-induced cell death, JNK-IN-7 enables the precise mapping of signaling nodes and supports reproducible, quantitative research outcomes. Ongoing studies continue to refine its applications in immune response regulation and translational disease models.

For product specifications and ordering, see the official JNK-IN-7 (A3519) product page.